ALLOVIR ALERT: Bragar Eagel & Squire, P.C. is Investigating AlloVir, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 06 2025
0mins
Source: Globenewswire
Legal Investigation: Bragar Eagel & Squire, P.C. is investigating potential claims against AlloVir, Inc. on behalf of long-term stockholders after a class action complaint was filed alleging that the company made false statements regarding its posoleucel Phase 3 studies.
Stock Price Impact: Following the announcement of discontinuing the posoleucel Phase 3 studies due to efficacy concerns, AlloVir's stock price plummeted by 67.38%, closing at $0.76 per share on December 22, 2023.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
